Mirjam B. Zeisel, Marine Turek, Thomas F. Baumert 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Laurent Mailly, Mirjam B. Zeisel, Thomas F. Baumert 
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Volume 65, Issue 1, Pages S82-S94 (October 2016)
Inflammasomes in liver diseases
Volume 61, Issue 4, Pages (October 2014)
Volume 50, Issue 4, Pages (April 2009)
Hepatic CD141+IFNλ+ DC subset: One against all?
Volume 67, Issue 3, Pages (September 2017)
Volume 42, Issue 6, Pages (June 2005)
Julien Bissonnette, Dominique Valla, Pierre-Emmanuel Rautou 
Mirjam B. Zeisel, Isabel Fofana, Samira Fafi-Kremer, Thomas F. Baumert 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 42, Issue 1, Pages (January 2005)
NS5A inhibitors in the treatment of hepatitis C
Stem cell therapies for liver failure and cirrhosis
Volume 65, Issue 1, Pages S82-S94 (October 2016)
Immigration and viral hepatitis
Determinants of hepatic effector CD8+ T cell dynamics
Heidi Barth, Eric Robinet, T. Jake Liang, Thomas F. Baumert 
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Hepatitis C virus entry and glucocorticosteroids
Living donor liver transplantation: is the hype over?
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Volume 69, Issue 2, Pages (August 2018)
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Biology of the immunomodulatory molecule HLA-G in human liver diseases
Jordan J. Feld, Graham R. Foster  Journal of Hepatology 
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Burcin Ekser, Eric Lagasse  Journal of Hepatology 
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Volume 44, Issue 2, Pages (February 2006)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Daniel J. Felmlee, Thomas F. Baumert  Journal of Hepatology 
Volume 62, Issue 3, Pages (March 2015)
Liver is liver and blood is blood, and finally the twain have met
Genomic risk of hepatitis C-related hepatocellular carcinoma
Advancing hepatitis B virus entry inhibitors
Autophagy in the liver Journal of Hepatology
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Volume 64, Issue 5, Pages (May 2016)
Volume 65, Issue 2, Pages (August 2016)
Volume 49, Issue 6, Pages (December 2008)
Volume 50, Issue 4, Pages (April 2009)
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Fei Xiao, Jane A. McKeating, Thomas F. Baumert  Journal of Hepatology 
miR-122 – A key factor and therapeutic target in liver disease
Volume 56, Issue 6, Pages (June 2012)
Immigration and viral hepatitis
The potential of induced pluripotent stem cell derived hepatocytes
HCV targeting of patients with cirrhosis
Volume 63, Issue 1, Pages (July 2015)
Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection  Isabelle Chemin,
Volume 51, Issue 2, Pages (August 2009)
HCV animal models and liver disease
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
EpCAM in hepatocytes and their progenitors
Eric Robinet, Thomas F. Baumert  Journal of Hepatology 
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Getting closer to the patient: Upgrade of hepatitis C virus infection in primary human hepatocytes  Mirjam B. Zeisel, Marine Turek, Thomas F. Baumert  Journal of Hepatology  Volume 53, Issue 2, Pages 388-389 (August 2010) DOI: 10.1016/j.jhep.2010.04.004 Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Microscale primary human hepatocyte co-cultures to study hepatitis C virus (HCV) infection. Schematic representation of micro-patterned co-cultures (MPCC) of primary human hepatocytes (PHH) for the study of HCV infection. (A) A polydimethylsiloxane (PDMS) stencil consisting of membranes with through-holes is applied at the bottom of cell culture wells. (B) A solution of collagen is then added to the wells to allow collagen to adsorb to the substrate via the through-holes. (C) Micro-patterned collagen is left on the substrate upon stencil removal. (D) PHH are seeded in the wells and selectively adhere to collagen-coated domains. (E) Subsequently, mouse embryonic fibroblasts (3T3-J2) are seeded into the remaining bare areas as feeder cells. (F) This generates MPCC PHH co-cultures. (G) PHH may be transduced with a fluorescent RFP-NLS-IPS reporter to visualize serum-derived HCV or recombinant cell culture-derived HCV (HCVcc) infection of PHH. HCV infection is indicated by nuclear translocation of the reporter. (H) Alternatively, Gaussia luciferase reporter viruses may be used to study HCVcc infection of PHH. Infection is detected by quantitation of luciferase secretion into cell culture supernatants. Journal of Hepatology 2010 53, 388-389DOI: (10.1016/j.jhep.2010.04.004) Copyright © 2010 European Association for the Study of the Liver Terms and Conditions